Skip to main content
Erschienen in:

Open Access 26.07.2024 | Invited Review

Crosstalk between bone and the immune system

verfasst von: Kazuo Okamoto

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 4/2024

Abstract

Bone functions not only as a critical element of the musculoskeletal system but also serves as the primary lymphoid organ harboring hematopoietic stem cells (HSCs) and immune progenitor cells. The interdisciplinary field of osteoimmunology has illuminated the dynamic interactions between the skeletal and immune systems, vital for the maintenance of skeletal tissue homeostasis and the pathogenesis of immune and skeletal diseases. Aberrant immune activation stimulates bone cells such as osteoclasts and osteoblasts, disturbing the bone remodeling and leading to skeletal disorders as seen in autoimmune diseases like rheumatoid arthritis. On the other hand, intricate multicellular network within the bone marrow creates a specialized microenvironment essential for the maintenance and differentiation of HSCs and the progeny. Dysregulation of immune–bone crosstalk in the bone marrow environment can trigger tumorigenesis and exacerbated inflammation. A comprehensive deciphering of the complex “immune–bone crosstalk” leads to a deeper understanding of the pathogenesis of immune diseases as well as skeletal diseases, and might provide insight into potential therapeutic approaches.
Hinweise
The original online version of this article was revised: figure 2 has been corrected.
A correction to this article is available online at https://​doi.​org/​10.​1007/​s00774-024-01547-x.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Bone is the key component of the locomotor system that supports and moves the body. The immune system is the host defense system that eliminates foreign substances such as microorganisms. Bone and the immune system may seem completely unrelated, but in fact, they interact and cooperate with each other in various physiological and pathological settings. Bone-resorbing cells osteoclasts belong to the monocyte/macrophage lineage, and receptor activator of NF-κB ligand (RANKL) is essential for immune organ development as well as osteoclast differentiation. Immune cells and bone cells share many regulatory factors such as cytokines, chemokines and receptors. Thus, the effects of abnormal immune activation such as autoimmunity can spill over into the skeletal system. Osteoimmunology was created and has developed as a new interdisciplinary field focusing on the crosstalk between the skeletal and immune systems [1]. The term “osteoimmunology” was first used in an editorial article in the Nature in 2000 in response to a paper on osteoclast regulation by T cells [2]. Since then, a variety of bone-immune interactions have been widely elucidated, not limited to the interaction between osteoclasts and T cells. Immune cells circulate in the body through blood and lymph vessels to peripheral tissues. Therefore, given the fact that immune cells attack a variety of tissues as seen in inflammatory diseases, it is evident that bone is not the only organ with which the immune system interacts. However, bone marrow is the primary lymphoid organ that provides the environment for differentiation and maintenance of hematopoietic stem cells (HSCs) and immune progenitor cells [3]. It should be noted that not only do the immune cells affect bone, but also bone cells regulate the immune system. In this review, I provide a comprehensive overview of the mutual relationship between the skeletal and immune systems in health and diseases by introducing the key background as well as the latest research progress.

RANKL, a representative factor linking bone and immunity

RANKL was reported in 1998 as a cytokine essential for osteoclast differentiation [4, 5], but it had already been identified in immunology the year before as a novel TNF family cytokine expressed on T cells [6, 7]. RANKL is a multifunctional cytokine that plays essential roles in not only bone but also immune regulation. Thus, RANKL is one of the most important osteoimmune molecules explicitly linking the skeletal and immune systems.

The cellular source of RANKL in bone remodeling

Based on analyses of cell type-specific RANKL-deficient mice, it has been shown that hypertrophic chondrocytes and osteoblasts are the major sources of RANKL in endochondral ossification during embryonic and growth stages, whereas osteocytes act as the main source of RANKL in adults [1, 8, 9]. RANKL expression in osteocytes is caused by mechanical loading, cellular senescence and cell death [10, 11]. In addition, bone marrow adipose progenitor cells labeled with Adiponectin-Cre have been shown as a source of RANKL for controlling trabecular bone mass in adults [12, 13] (Fig. 1). On the other hand, osteoprotegerin (OPG), a decoy receptor for RANKL, is mainly produced by newly formed osteocytes near the surface of cortical bone [14]. Long-term treatment with anti-RANKL antibody denosumab decreased new osteocytes and OPG production, contributing to rebound resorption after denosumab discontinuation.

Roles of RANKL in the immune system

RANKL is essential for the differentiation of medullary thymic epithelial cells (mTECs). The main source of RANKL-producing cells for mTEC differentiation are single positive thymocytes after birth [15]. During ontogeny, lymphoid tissue inducer (LTi) cells, γδ T cells and natural killer T (NKT) cells express RANKL for mTEC development [1]. Furthermore, RANKL-induced mTEC differentiation was involved in the expansion of natural regulatory T (Treg) cells in pregnancy. Thymic deletion of the Tnfrsf11a gene (encodes RANK, the receptor for RANKL) caused the reduced accumulation of natural regulatory T (Treg) cells in the placenta and visceral adipose tissue, resulting in miscarriages and gestational diabetes [16]. RANKL- and RANK-deficient mice also showed a systemic loss of lymph node formation [17]. Activation of RANK+ lymphatic endothelial cells by LTi cells via RANKL in the lymphoid anlagen, followed by activation of mesenchymal lymphoid tissue organizer (LTo) cells, is necessary for lymph node organogenesis [18]. In addition, RANKL signal is required for microfold cell (M cell) differentiation in the gut. Subepithelial mesenchymal cells of the gut-associated lymphoid tissues induce M cell differentiation by supplying RANKL to RANK-positive intestinal epithelial cells [19]. Given that osteoclasts are required for the formation of the bone marrow cavity, RANKL could be considered a cytokine for the development of immune organs (Fig. 1).
T cell-derived RANKL does not contribute to bone metabolism but triggered chronic inflammation of the central nervous system by interacting with RANK-expressing astrocytes in multiple sclerosis [20]. In the tumor microenvironment of breast cancer, RANKL expressed on Treg cells stimulated tumor cells to promote the metastatic activity [21]. Moreover, RANKL on epidermal cells induces Treg cell proliferation via Langerhans cells, suppressing inflammatory skin diseases. The RANKL/RANK system exerts immunological functions not only in the immune organ development but also in various pathological conditions including inflammatory diseases and cancer.

Local regulation of the RANKL/RANK system

RANKL is synthesized as a membrane-bound molecule, which is cleaved into the soluble form by proteases. Although both forms function as agonistic ligands for RANK, soluble RANKL-deficient mice did not show any discernible osteopetrotic phenotype [22]. In addition, soluble RANKL did not contribute to pathological osteoclast activation in ovariectomy-induced osteoporosis and periodontitis [22, 23], suggesting that membrane-bound RANKL mainly functions in osteoclast differentiation in vivo. Furthermore, unlike RANKL-null mice, soluble RANKL-deficient mice had normal development of the immune organs, including mTEC differentiation, lymph node organogenesis and M cell differentiation [22]. Thus, soluble RANKL is dispensable for physiological regulation of bone and immune systems. OPG also circulates in the blood as a soluble protein. Analyses of osteoblast-specific, thymic epithelial cell-specific and intestinal epithelial cell-specific OPG-deficient mice have revealed that bone remodeling, mTEC differentiation and M cell differentiation is controlled by OPG locally produced in bone, thymus and intestine, respectively, but not by circulating OPG [24]. The findings further revealed the importance of local regulation of the RANKL/RANK system.

Osteoclasts, key hematopoietic lineage cells involved in the skeletal system

Osteoclast is one of the crucial hematopoietic lineage cells in bone, and studies on mechanism of osteoclast differentiation have highlighted the similarities between bone and immune cells. Osteoclasts are large multinucleated cells formed by the fusion of myeloid lineage precursor cells. HSCs support hematopoiesis throughout life after birth and give rise to a wide variety of immune cells. However, recent findings indicate that tissue-resident macrophages such as Kupffer cells in the liver and microglia in the brain originate from the primitive erythro-myeloid progenitors (EMPs) in the yolk sac at the early embryonic stage [25]. Regarding osteoclasts, yolk sac-derived EMPs give rise to osteoclasts during embryonic and fetal development, whereas osteoclasts arise from HSC-derived monocyte/macrophage precursor cells in postnatal life [26, 27]. Osteoclast differentiation is induced by stimulation of RANKL, which is produced by mesenchymal cells such as osteoblastic lineage cells [1, 17]. Downstream of its receptor RANK, NF-κB and mitogen-activated protein kinases (MAPKs) are activated via TNF receptor-associated factor (TRAF) 6 and induce the expression of nuclear factor of activated T cells (NFATc1) [1, 28]. NFATc1 was originally identified as a transcription factor for T cell activation, but in osteoclasts, it functions as the master regulator for osteoclastogenesis. c-Fos is also induced by RANKL stimulation via CREB and NF-κB, and crucially involved in NFATc1 induction as the AP-1 dimer formed with Jun proteins [1, 2831]. Notably, c-Fos is known to play a critical role in osteosarcoma development as well as in the regulation of gene expression downstream of immune-related signals such as antigen receptors and cytokine receptors. NFATc1 directly induces the expression of genes related to cell morphological changes, fusion and bone resorption activity of osteoclasts, cooperating with other transcriptional factors such as AP-1, MITF and PU.1 [1]. In addition, signals from immunoglobulin-like receptors associated with DAP12 and FcRγ act as co-stimulators for RANK signaling, leading to activation of Tec and Btk, known as important tyrosine kinases downstream of antigen receptors in lymphocytes. Tec and Btk in turn trigger calcium signaling essential for induction and activation of NFATc1 [1]. Thus, molecules with well-known functions in immune cells were unexpectedly found to play critical roles in osteoclast differentiation. Studies on RANKL signaling in osteoclasts have revealed striking similarities between bone and immune cells.

Regulation of bone by the immune system

Immune-bone crosstalks in rheumatoid arthritis

Rheumatoid arthritis (RA) is one of the most representative skeletal disorders triggered by an abnormal immune activation. In RA, autoimmune synovial inflammation causes bone and cartilage destruction in the joints. In the inflamed synovium, IL-17-producing helper T cells, Th17 cells, induce the production of the inflammatory cytokines such as TNF, IL-6 and IL-1, thereby promoting local inflammation. In addition to these proinflammatory cytokines, IL-17 produced by Th17 cells stimulates synovial fibroblasts to induce RANKL expression, leading to abnormal osteoclast activation [32, 33]. The synovial fibroblasts in RA can be divided into two major types: inflammatory fibroblasts located in the sublining layer that secrete the inflammatory cytokines and chemokines, and tissue-destructive fibroblasts in the lining layer that express RANKL and matrix metalloproteinases (MMPs) [34]. NOTCH ligands by endothelial cells, TNF and leukemia inhibitory factor (LIF) contribute to the polarization of inflammatory synovial fibroblasts [3537]. On the other hand, the transcription factor ETS1 drives the polarization toward tissue-destructive fibroblasts by controlling gene expression of RANKL and MMPs [38]. B lymphocytes also contribute to bone loss in arthritis. Immune complexes act directly on Fcγ receptors on osteoclasts to promote the osteoclastogenesis [39, 40]. Desialylated immune complexes are highly effective in promoting osteoclast differentiation [39], and sialylation of IgG-Fc is controlled by an IL-23–Th17 cell-dependent process [41]. Furthermore, RANKL produced by plasma cell is involved in periarticular bone loss, an osteoporotic lesion observed in the bone adjacent to joints in RA [42]. Recent studies using mouse models of RA has revealed that a distinct population of CX3CR1hiLy6CintF4/80+MHC-II+ macrophages function as osteoclast precursors in arthritis joints [43]. Bone marrow-derived circulating monocytes migrate to the synovium and then differentiate into the unique osteoclast progenitors in arthritic conditions. Osteoblastic bone formation is also affected by the immune factors in arthritis joints. In the synovium, TNF induces the production of the Wnt inhibitor Dickkopf-related protein 1, leading to suppression of bone formation [44]. Sclerostin, another inhibitor of the Wnt signaling pathway, is also elevated in the synovium [45]. Sclerostin-neutralizing antibody inhibited periarticular and systemic bone loss in the mouse models of RA [46], whereas genetic Sost (encoding sclerostin) deletion aggravated joint inflammation and destruction in TNF transgenic mice because sclerostin blocks signaling pathways downstream of TNF [45]. Collectively, the complex immune-bone crosstalk among lymphocytes, synovial fibroblasts, osteoclasts and osteoblasts in arthritic joints underlies the pathogenesis of bone destruction in RA (Fig. 2).

Immune-mediated bone regulation in other diseases

IL-17-type immune responses also contributes to the pathogenesis of other inflammatory bone diseases. In periodontitis, IL-17, IL-6 and neutrophils-derived oncostatin M induced RANKL in osteoblasts and periodontal ligament cells, leading to periodontal bone destruction [23, 47]. In a mouse model of ankylosing spondylitis (AS), unique IL-23R+ T cells expressing IL-17 and IL-22 induced ossification of the tendon–ligament attachment [48]. Studies of human AS patients have shown the pathological significance of IL-17 production by invariant NKT cells, γδ T cells and innate lymphoid cells [49]. In mouse models of chronic IL-17A-mediated skin inflammation, which mimics the psoriatic arthritis, IL-17 from γδ T cells, ILCs and keratinocytes negatively regulated osteogenesis by suppressing the Wnt signaling [50]. In a mouse model of osteoarthritis (OA) induced by anterior cruciate ligament transection, IL-17 produced by Th17 and γδ T cells triggered the senescence in the articular cartilage, and senescent fibroblasts in the joints further promoted Th17 skewing, indicating the bidirectional connection between IL-17-type immunity and cell senescence in OA [51]. On the other hand, studies on a mouse model using osteosarcoma cell line AX have shown that TNF by tumor-associated macrophages and IL-17 produced by CD4+ lymphocytes maintain osteosarcoma cells in an undifferentiated state by inhibiting their osteoblastic differentiation [52, 53]. The findings suggested that inhibitory effects of IL-17 and TNF on osteoblastogenesis contribute to osteosarcoma progression. Unlike IL-17, IFN-γ, which is a key cytokine of Th1 cells and cytotoxic CD8 T cells, acts as a potent inhibitor of osteoclast differentiation [2, 32]. Mendelian susceptibility to mycobacterial disease (MSMD), a primary immunodeficiency caused by IFN-γR1, IFN-γR2 or signal transducer and activator of transcription (STAT) 1 deficiency, leads to vulnerability to intramacrophagic pathogens and osteomyelitis. In MSMD patients, defective IFN-γ-STAT1 signaling results in abnormal activation of osteoclasts, possibly causing multifocal osteomyelitis [54]. Therefore, it is considered that the physiological significance of IFN-γ-mediated suppression of osteoclasts might be to limit excessive bone resorption during infections.

Immuno-bone crosstalk in bone healing

The immune cells also play critical roles in the bone regeneration process after the injury. Immediately after bone fracture, blood vessels at the fracture site get ruptured causing bleeding, leading to the accumulation of lymphocytes and macrophages that triggers inflammation. IL-17-producing γδ T cells accumulating at the fracture site stimulate directly PDGFRα+Sca1+ mesenchymal progenitor cells, thereby inducing cell proliferation and osteoblast differentiation [55]. On the other hand, effector memory CD8 T cells negatively regulated bone regeneration by inhibiting the osteogenesis of mesenchymal progenitor cells via IFN-γ and TNF [56]. Bone fractures in the elderly tend to heal more slowly than those in younger patients. Studies on mouse models of bone fracture showed that the age-related decline in bone repair was attributed to a decrease in macrophage-produced low-density lipoprotein receptor-related protein 1 (Lrp1) that rejuvenate fracture repair [57]. Immune cells exhibit different outputs to bone remodeling by acting on osteoclasts, osteoblasts, fibroblasts and mesenchymal stem cells, depending on the physiological and pathological context [58].

Regulation of the immune system by bone: bone marrow hematopoiesis

In the bone marrow, mesenchymal lineage cells build up the specialized microenvironment for the maintenance of HSC and the progeny. LepR+CXCL12+ mesenchymal stem cells serve as the HSC niche with the high level of production of SCF and CXCL12, both of which are required for HSC maintenance and retention [59]. Notably, LepR+CXCL12+ mesenchymal stem cells are a main source of osteoblasts and adipocytes in adult bone marrow [60], and can undergo fibrotic differentiation under pathological conditions (Fig. 3A). On the other hand, osteoblasts maintain common lymphoid progenitors in the bone marrow by producing IL-7 and DLL4 [61, 62]. Recently, it has been shown that osteoblast-derived extracellular ATP is required for plasm cell maintenance in the bone marrow [63] (Fig. 3A). Changes in the osteoblastic status critically interfere with normal hematopoiesis. In sepsis, increased G-CSF causes a drastic reduction of osteoblasts in the bone marrow, resulting in a decrease in common lymphocyte progenitor cells and lymphopenia [61]. Activation of β-catenin in osteoblasts induced acute myeloid leukemia [64], and activating mutations of the protein tyrosine phosphatase SHP2 resulted in the development of leukemia [65]. Deletion of Dicer1 in osteoblasts led to decreased expression of the Sbds gene, which functions in ribosome synthesis, leading to myelodysplasia and leukemia [66]. The SBDS gene is frequently mutated in Shwachman–Diamond syndrome, and Sbds-deficient mesenchymal cells induced genotoxic stress in HSCs via S100A8/9 production [67]. Osteoblastic lineage cells are essential for the proper maintenance of lymphoid progenitors in the bone marrow, while their alteration can lead to hematological malignancies (Fig. 3B).
Since osteoclasts form the bone marrow cavity, their involvement in the regulation of HSCs has also been examined as a topic of significance. Osteoclasts secrete MMP9 and cathepsin K to degrade CXCL12, thereby abrogating the HSC retention to the niche cells [68], suggesting that osteoclastic bone resorption promotes HSC mobilization from the bone marrow. However, G-CSF-induced HSC mobilization was not suppressed but rather enhanced in mice treated with alendronate or neutralizing RANKL antibody, and osteoclast-deficient mice including op/op, c-Fos-deficient and RANKL-deficient mice [69]. Consistent with the findings, it was reported that treatment with pamidronate or OPG-Fc did not reduce HSC mobilization to the periphery [70, 71]. On the other hand, osteoclast inhibition resulted in a decrease in the frequency and number of HSCs and B cells through the modulation of the bone marrow mesenchymal cells [72, 73]. It was also reported that calcium-sensing receptor on HSCs is required for their homing to the endosteal niche, suggesting that high Ca2+ level resulting from osteoclastic bone resorption is involved in HSC maintenance [74]. Therefore, osteoclast may play a role in HSC regulation in the bone marrow under in some cases, but at least they are less involved in G-CSF-induced HSC mobilization.

Impacts of osteoporosis on the immune system

Given that osteoclasts and osteoblasts are somehow involved in HSC regulation in the bone marrow, it would be possible that the immune system is influenced by the osteoporotic conditions. The severe osteoporosis caused by OPG-deficiency resulted in decreased G-CSF-induced mobilization of HSCs [69]. Together with the findings that HSC mobilization was increased by pharmacological or genetic inhibition of osteoclast activity as described above, osteoclast activity might negatively regulate HSC mobilization. Human studies on postmenopausal osteoporosis have reported that the number of several memory B cell subsets were significantly lower in women with osteoporosis and positively correlated to bone mineral density [75]. Bioinformatics analysis using expression profiles of bone samples derived from postmenopausal osteoporosis patients suggested that the frequencies of T and NK cells increases during the progression of postmenopausal osteoporosis [76]. In addition, the expression level of the osteoclastogenic cytokines such as IL-17, TNF and IL-6 were upregulated by estrogen deficiency [77]. These findings suggested that the immune cell development or activation status can be affected by postmenopausal osteoporosis. Furthermore, it was reported that ovariectomy caused gut permeability to induce Th17 cell expansion in the gut, which contributes to bone loss [78]. However, the role of lymphocytes in estrogen deficiency-induced bone loss remains controversial, since neither TCRα-deficient nor Rag2-deficent mice display any obvious bone phenotype. Since factors causing osteoporosis such as sex hormone changes, aging and autoimmunity can directly affect the immune system, caution is needed to determine the causal relationship between bone loss and immune cell changes in osteoporosis.
Bone structure and mass change with age, characterized by decreased bone remodeling, decreased bone mass, increased bone porosity, cortical thinning, expansion of bone marrow fat and delayed bone regeneration [79, 80]. In addition, aging also affects hematopoiesis in the bone marrow, which shows a bias toward myeloid differentiation with aging [81]. The myeloid skewing during aging was reported to result from skeletal stem cell aging [79], and IL-1 production by osteoprogenitors and arteriolar endothelial cells [82]. Skeletal stem cell aging was also implicated in aging-impaired skeletal regeneration [79]. Conversely, grancalcin production by aged neutrophils and macrophages promoted skeletal aging including low bone formation and marrow fat accumulation [83]. Recently, light-sheet imaging of the skeletal tissues has revealed lymphatic vessels in bones, which contributed to bone and hematopoietic regeneration after stress [84]. Aging led to impairment in stress-induced lymphatic expansion in the bone marrow, reducing the regeneration abilities in the bone. Aging significantly alters the mode of crosstalk between bone and the immune system in the bone marrow microenvironment.

Changes in bone marrow microenvironment by exercise, malnutrition and tumors

Physical activity affects the bone marrow environment, modulating the immune cell differentiation. Exercise-induced reduction of leptin production in adipose tissue promoted CXCL12 expression in LepR+ mesenchymal stem cells in the bone marrow, keeping HSCs in a quiescent phase [85]. As a result, inflammatory leukocyte decreased, contributing to attenuation of cardiovascular inflammation. Exercise induced the secretion of reticulocalbin-2 from bone marrow macrophages [86]. Reticulocalbin-2 enhanced bone marrow fat lipolysis, leading to osteogenesis and lymphopoiesis.
Nutritional status also has a profound effect on the immune system by altering the bone marrow environment. Nutrient deprivation increased CXCL13 production in the bone marrow, which induced migration of naive B cells from intestinal Peyer’s patches (PP) into the bone marrow [87]. Naïve B cells swiftly migrated back to PP in response to refeeding, and thus repeated fasting impacted B cell dynamics, resulting in attenuated antigen-specific mucosal immune responses. In addition, dietary restriction increased memory T cell accumulation in the bone marrow via adipocytes, CXCR4-CXCL12 and S1P-S1P1R [88]. Malnutrition-induced homing of memory T cells to bone marrow was associated with enhanced immunity against infection and tumors [88].
Tumor cells can escape the immune attack by establishing the microenvironment that suppresses anti-tumor immune responses by incorporating immune-suppressive cells and factors. Interestingly, tumors not only act locally on immune cells around tumor tissues, but also stimulates the osteoblastic cells in the bone marrow, thereby eliciting the development of immune-suppressive cells. Lung cancer-derived soluble receptor for advanced glycation end products (sRAGE) remotely activated osteoblasts in bones. In turn, osteoblasts supply lung tumor with pro-tumorigenic SiglecFhigh neutrophils, resulting in tumor progression [89]. Skin cancer remotely acts on osteoblasts and osteocytes to promote DKK1 production. DKK1 induced the expansion of myeloid-derived suppressor cells, which suppresses the anti-tumor immune response [90]. Through the modulation of bone marrow osteoblasts and stromal cells organized into the hematopoietic niche, various pathophysiological stresses including aging, physical exercise, malnutritional and tumors substantially impact the immune responses (Fig. 3C).

Concluding remarks

The review outlines the impact of the immune system on bone in the context of tissue repair and destruction, and the regulation of the immune cell differentiation by bone cells in the bone marrow, shedding light on the bidirectional reciprocal relationship between the two systems. The findings gained from osteoimmunology research have greatly contributed to the clinical and drug discovery fields, particularly in the development of therapeutic agents for RA. Elucidation of the effects of immune cells/factors on bone has led to the understanding of the mechanism of action of drugs such as immune-modulating biologics on bone destruction in arthritis. On the other hand, much knowledge has been accumulated about immune regulation by bone cells in the bone marrow, and its significance in various physiological and pathological settings, such as aging and cancer, is becoming clear. The next step for osteoimmunology would be how to feed these findings back into clinical practice, for example, in the prevention and treatment for cancer and aging-related disorders as well as various diseases of bone and/or the immune system. Recent advances in single-cell omics technology have made it possible to analyze the heterogeneous immune cell populations at high resolution, even in human peripheral blood and tissue samples. The technique of human immune phenotyping has been applied in various clinical studies, and human immunology is making great progress. However, it is still difficult to decipher the multicellular dynamics of human bone and bone marrow at the single-cell level. In addition to LepR+CXCL12+ bone marrow mesenchymal stem cells, novel types of mesenchymal stem cells such as periosteal stem cells and growth plate resting zone stem cells, vertebral skeletal stem cells have recently been discovered, further spotlighting the extremely heterogeneous nature of mesenchymal cells in bone. In deciphering the immune–bone crosstalk in the bone marrow, we must keep in mind that the bone marrow microenvironment is composed of an extremely diverse population of cells belonging not only to bone metabolism and the immune system, but also to nervous and vascular systems. Further development of multi-omics and imaging techniques would offer a comprehensive view of diverse cellular dynamics in bone, enhancing our understanding of the complex regulatory mechanisms that govern the interplay between the skeletal and immune systems.

Acknowledgements

This work was supported in part by the Japan Agency for Medical Research and Development (AMED), Core Research for Evolutional Science and Technology (CREST) (JP23gm1210008 and JP23gm1710003); JST FOREST Program (Grant Number JPMJFR205Z, Japan); Grants-in-Aid for Scientific Research S (21H05046) and Scientific Research B (22H03195) from the Japan Society for the Promotion of Science (JSPS); a grant from The Japanese Society for Bone and Mineral Research Rising Stars Grant.

Declarations

Conflict of interest

The Department of Osteoimmunology is an endowment department, supported with unrestricted grants from AYUMI Pharmaceutical Corporation, ELECOM, JCR Pharmaceuticals, Kondo Cotton Spinning, Meiji, MIKIHOUSE, MITSUI FUDOSAN, Noevir, TAKENAKA, TENNENBUTSU IKAGAKU KENKYU ZAIDAN and Yakult.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Dent – Das Online-Abo der Zahnmedizin

Online-Abonnement

Mit e.Dent erhalten Sie Zugang zu allen zahnmedizinischen Fortbildungen und unseren zahnmedizinischen und ausgesuchten medizinischen Zeitschriften.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Weitere Produktempfehlungen anzeigen
Literatur
1.
Zurück zum Zitat Okamoto K, Nakashima T, Shinohara M, Negishi-Koga T, Komatsu N, Terashima A, Sawa S, Nitta T, Takayanagi H (2017) Osteoimmunology: the conceptual framework unifying the immune and skeletal systems. Physiol Rev 97:1295–1349PubMedCrossRef Okamoto K, Nakashima T, Shinohara M, Negishi-Koga T, Komatsu N, Terashima A, Sawa S, Nitta T, Takayanagi H (2017) Osteoimmunology: the conceptual framework unifying the immune and skeletal systems. Physiol Rev 97:1295–1349PubMedCrossRef
2.
Zurück zum Zitat Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 408:600–605PubMedCrossRef Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 408:600–605PubMedCrossRef
3.
Zurück zum Zitat Sugiyama T, Omatsu Y, Nagasawa T (2019) Niches for hematopoietic stem cells and immune cell progenitors. Int Immunol 31:5–11PubMedCrossRef Sugiyama T, Omatsu Y, Nagasawa T (2019) Niches for hematopoietic stem cells and immune cell progenitors. Int Immunol 31:5–11PubMedCrossRef
4.
Zurück zum Zitat Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176PubMedCrossRef Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176PubMedCrossRef
5.
Zurück zum Zitat Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95:3597–3602PubMedPubMedCentralCrossRef Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95:3597–3602PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175–179PubMedCrossRef Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175–179PubMedCrossRef
7.
Zurück zum Zitat Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS 3rd, Frankel WN, Lee SY, Choi Y (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272:25190–25194PubMedCrossRef Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS 3rd, Frankel WN, Lee SY, Choi Y (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272:25190–25194PubMedCrossRef
8.
Zurück zum Zitat Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, Penninger JM, Takayanagi H (2011) Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17:1231–1234PubMedCrossRef Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, Penninger JM, Takayanagi H (2011) Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17:1231–1234PubMedCrossRef
9.
Zurück zum Zitat Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O’Brien CA (2011) Matrix-embedded cells control osteoclast formation. Nat Med 17:1235–1241PubMedPubMedCentralCrossRef Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O’Brien CA (2011) Matrix-embedded cells control osteoclast formation. Nat Med 17:1235–1241PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Yan M, Tsukasaki M, Muro R, Ando Y, Nakamura K, Komatsu N, Nitta T, Okamura T, Okamoto K, Takayanagi H (2023) Identification of an intronic enhancer regulating RANKL expression in osteocytic cells. Bone Res 11:43PubMedPubMedCentralCrossRef Yan M, Tsukasaki M, Muro R, Ando Y, Nakamura K, Komatsu N, Nitta T, Okamura T, Okamoto K, Takayanagi H (2023) Identification of an intronic enhancer regulating RANKL expression in osteocytic cells. Bone Res 11:43PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Kim HN, Xiong J, MacLeod RS, Iyer S, Fujiwara Y, Cawley KM, Han L, He Y, Thostenson JD, Ferreira E, Jilka RL, Zhou D, Almeida M, O’Brien CA (2020) Osteocyte RANKL is required for cortical bone loss with age and is induced by senescence. JCI Insight 5:e138815PubMedPubMedCentralCrossRef Kim HN, Xiong J, MacLeod RS, Iyer S, Fujiwara Y, Cawley KM, Han L, He Y, Thostenson JD, Ferreira E, Jilka RL, Zhou D, Almeida M, O’Brien CA (2020) Osteocyte RANKL is required for cortical bone loss with age and is induced by senescence. JCI Insight 5:e138815PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Yu W, Zhong L, Yao L, Wei Y, Gui T, Li Z, Kim H, Holdreith N, Jiang X, Tong W, Dyment N, Liu XS, Yang S, Choi Y, Ahn J, Qin L (2021) Bone marrow adipogenic lineage precursors promote osteoclastogenesis in bone remodeling and pathologic bone loss. J Clin Invest 131:e140214PubMedPubMedCentralCrossRef Yu W, Zhong L, Yao L, Wei Y, Gui T, Li Z, Kim H, Holdreith N, Jiang X, Tong W, Dyment N, Liu XS, Yang S, Choi Y, Ahn J, Qin L (2021) Bone marrow adipogenic lineage precursors promote osteoclastogenesis in bone remodeling and pathologic bone loss. J Clin Invest 131:e140214PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Hu Y, Li X, Zhi X, Cong W, Huang B, Chen H, Wang Y, Li Y, Wang L, Fang C, Guo J, Liu Y, Cui J, Cao L, Weng W, Zhou Q, Wang S, Chen X, Su J (2021) RANKL from bone marrow adipose lineage cells promotes osteoclast formation and bone loss. EMBO Rep 22:e52481PubMedPubMedCentralCrossRef Hu Y, Li X, Zhi X, Cong W, Huang B, Chen H, Wang Y, Li Y, Wang L, Fang C, Guo J, Liu Y, Cui J, Cao L, Weng W, Zhou Q, Wang S, Chen X, Su J (2021) RANKL from bone marrow adipose lineage cells promotes osteoclast formation and bone loss. EMBO Rep 22:e52481PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Fu Q, Bustamante-Gomez NC, Reyes-Pardo H, Gubrij I, Escalona-Vargas D, Thostenson JD, Palmieri M, Goellner JJ, Nookaew I, Barnes CL, Stambough JB, Ambrogini E, O’Brien CA (2023) Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation. JCI Insight 8:e167790CrossRefPubMedPubMedCentral Fu Q, Bustamante-Gomez NC, Reyes-Pardo H, Gubrij I, Escalona-Vargas D, Thostenson JD, Palmieri M, Goellner JJ, Nookaew I, Barnes CL, Stambough JB, Ambrogini E, O’Brien CA (2023) Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation. JCI Insight 8:e167790CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Hikosaka Y, Nitta T, Ohigashi I, Yano K, Ishimaru N, Hayashi Y, Matsumoto M, Matsuo K, Penninger JM, Takayanagi H, Yokota Y, Yamada H, Yoshikai Y, Inoue J, Akiyama T, Takahama Y (2008) The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity 29:438–450PubMedCrossRef Hikosaka Y, Nitta T, Ohigashi I, Yano K, Ishimaru N, Hayashi Y, Matsumoto M, Matsuo K, Penninger JM, Takayanagi H, Yokota Y, Yamada H, Yoshikai Y, Inoue J, Akiyama T, Takahama Y (2008) The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity 29:438–450PubMedCrossRef
16.
Zurück zum Zitat Paolino M, Koglgruber R, Cronin SJF, Uribesalgo I, Rauscher E et al (2021) RANK links thymic regulatory T cells to fetal loss and gestational diabetes in pregnancy. Nature 589:442–447PubMedCrossRef Paolino M, Koglgruber R, Cronin SJF, Uribesalgo I, Rauscher E et al (2021) RANK links thymic regulatory T cells to fetal loss and gestational diabetes in pregnancy. Nature 589:442–447PubMedCrossRef
17.
Zurück zum Zitat Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315–323PubMedCrossRef Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315–323PubMedCrossRef
18.
Zurück zum Zitat Onder L, Morbe U, Pikor N, Novkovic M, Cheng HW, Hehlgans T, Pfeffer K, Becher B, Waisman A, Rulicke T, Gommerman J, Mueller CG, Sawa S, Scandella E, Ludewig B (2017) Lymphatic endothelial cells control initiation of lymph node organogenesis. Immunity 47:80–92PubMedCrossRef Onder L, Morbe U, Pikor N, Novkovic M, Cheng HW, Hehlgans T, Pfeffer K, Becher B, Waisman A, Rulicke T, Gommerman J, Mueller CG, Sawa S, Scandella E, Ludewig B (2017) Lymphatic endothelial cells control initiation of lymph node organogenesis. Immunity 47:80–92PubMedCrossRef
19.
Zurück zum Zitat Nagashima K, Sawa S, Nitta T, Tsutsumi M, Okamura T, Penninger JM, Nakashima T, Takayanagi H (2017) Identification of subepithelial mesenchymal cells that induce IgA and diversify gut microbiota. Nat Immunol 18:675–682PubMedCrossRef Nagashima K, Sawa S, Nitta T, Tsutsumi M, Okamura T, Penninger JM, Nakashima T, Takayanagi H (2017) Identification of subepithelial mesenchymal cells that induce IgA and diversify gut microbiota. Nat Immunol 18:675–682PubMedCrossRef
20.
Zurück zum Zitat Guerrini MM, Okamoto K, Komatsu N, Sawa S, Danks L, Penninger JM, Nakashima T, Takayanagi H (2015) Inhibition of the TNF family Cytokine RANKL prevents autoimmune inflammation in the central nervous system. Immunity 43:1174–1185PubMedCrossRef Guerrini MM, Okamoto K, Komatsu N, Sawa S, Danks L, Penninger JM, Nakashima T, Takayanagi H (2015) Inhibition of the TNF family Cytokine RANKL prevents autoimmune inflammation in the central nervous system. Immunity 43:1174–1185PubMedCrossRef
21.
Zurück zum Zitat Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470:548–553PubMedPubMedCentralCrossRef Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470:548–553PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Asano T, Okamoto K, Nakai Y, Tsutsumi M, Muro R, Suematsu A, Hashimoto K, Okamura T, Ehata S, Nitta T, Takayanagi H (2019) Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone. Nat Metab 1:868–875PubMedCrossRef Asano T, Okamoto K, Nakai Y, Tsutsumi M, Muro R, Suematsu A, Hashimoto K, Okamura T, Ehata S, Nitta T, Takayanagi H (2019) Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone. Nat Metab 1:868–875PubMedCrossRef
23.
Zurück zum Zitat Tsukasaki M, Komatsu N, Nagashima K, Nitta T, Pluemsakunthai W, Shukunami C, Iwakura Y, Nakashima T, Okamoto K, Takayanagi H (2018) Host defense against oral microbiota by bone-damaging T cells. Nat Commun 9:701PubMedPubMedCentralCrossRef Tsukasaki M, Komatsu N, Nagashima K, Nitta T, Pluemsakunthai W, Shukunami C, Iwakura Y, Nakashima T, Okamoto K, Takayanagi H (2018) Host defense against oral microbiota by bone-damaging T cells. Nat Commun 9:701PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Tsukasaki M, Asano T, Muro R, Huynh NC, Komatsu N, Okamoto K, Nakano K, Okamura T, Nitta T, Takayanag H (2020) OPG production matters where it happened. Cell Rep 32:108124PubMedCrossRef Tsukasaki M, Asano T, Muro R, Huynh NC, Komatsu N, Okamoto K, Nakano K, Okamura T, Nitta T, Takayanag H (2020) OPG production matters where it happened. Cell Rep 32:108124PubMedCrossRef
26.
Zurück zum Zitat Jacome-Galarza CE, Percin GI, Muller JT, Mass E, Lazarov T, Eitler J, Rauner M, Yadav VK, Crozet L, Bohm M, Loyher PL, Karsenty G, Waskow C, Geissmann F (2019) Developmental origin, functional maintenance and genetic rescue of osteoclasts. Nature 568:541–545PubMedPubMedCentralCrossRef Jacome-Galarza CE, Percin GI, Muller JT, Mass E, Lazarov T, Eitler J, Rauner M, Yadav VK, Crozet L, Bohm M, Loyher PL, Karsenty G, Waskow C, Geissmann F (2019) Developmental origin, functional maintenance and genetic rescue of osteoclasts. Nature 568:541–545PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Yahara Y, Barrientos T, Tang YJ, Puviindran V, Nadesan P, Zhang H, Gibson JR, Gregory SG, Diao Y, Xiang Y, Qadri YJ, Souma T, Shinohara ML, Alman BA (2020) Erythromyeloid progenitors give rise to a population of osteoclasts that contribute to bone homeostasis and repair. Nat Cell Biol 22:49–59PubMedPubMedCentralCrossRef Yahara Y, Barrientos T, Tang YJ, Puviindran V, Nadesan P, Zhang H, Gibson JR, Gregory SG, Diao Y, Xiang Y, Qadri YJ, Souma T, Shinohara ML, Alman BA (2020) Erythromyeloid progenitors give rise to a population of osteoclasts that contribute to bone homeostasis and repair. Nat Cell Biol 22:49–59PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889–901PubMedCrossRef Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889–901PubMedCrossRef
29.
Zurück zum Zitat Wang ZQ, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF (1992) Bone and haematopoietic defects in mice lacking c-fos. Nature 360:741–745PubMedCrossRef Wang ZQ, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF (1992) Bone and haematopoietic defects in mice lacking c-fos. Nature 360:741–745PubMedCrossRef
30.
Zurück zum Zitat Johnson RS, Spiegelman BM, Papaioannou V (1992) Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71:577–586PubMedCrossRef Johnson RS, Spiegelman BM, Papaioannou V (1992) Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71:577–586PubMedCrossRef
31.
Zurück zum Zitat Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF (1994) c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266:443–448PubMedCrossRef Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF (1994) c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266:443–448PubMedCrossRef
32.
Zurück zum Zitat Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203:2673–2682PubMedPubMedCentralCrossRef Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203:2673–2682PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, Tanaka S, Bluestone JA, Takayanagi H (2014) Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med 20:62–68PubMedCrossRef Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, Tanaka S, Bluestone JA, Takayanagi H (2014) Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med 20:62–68PubMedCrossRef
34.
Zurück zum Zitat Croft AP, Campos J, Jansen K, Turner JD, Marshall J et al (2019) Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570:246–251PubMedPubMedCentralCrossRef Croft AP, Campos J, Jansen K, Turner JD, Marshall J et al (2019) Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570:246–251PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Wei K, Korsunsky I, Marshall JL, Gao A, Watts GFM et al (2020) Notch signalling drives synovial fibroblast identity and arthritis pathology. Nature 582:259–264PubMedPubMedCentralCrossRef Wei K, Korsunsky I, Marshall JL, Gao A, Watts GFM et al (2020) Notch signalling drives synovial fibroblast identity and arthritis pathology. Nature 582:259–264PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Armaka M, Ospelt C, Pasparakis M, Kollias G (2018) The p55TNFR-IKK2-Ripk3 axis orchestrates arthritis by regulating death and inflammatory pathways in synovial fibroblasts. Nat Commun 9:618PubMedPubMedCentralCrossRef Armaka M, Ospelt C, Pasparakis M, Kollias G (2018) The p55TNFR-IKK2-Ripk3 axis orchestrates arthritis by regulating death and inflammatory pathways in synovial fibroblasts. Nat Commun 9:618PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Nguyen HN, Noss EH, Mizoguchi F, Huppertz C, Wei KS, Watts GFM, Brenner MB (2017) Autocrine loop involving IL-6 family member LIF, LIF receptor, and STAT4 drives sustained fibroblast production of inflammatory mediators. Immunity 46:220–232PubMedPubMedCentralCrossRef Nguyen HN, Noss EH, Mizoguchi F, Huppertz C, Wei KS, Watts GFM, Brenner MB (2017) Autocrine loop involving IL-6 family member LIF, LIF receptor, and STAT4 drives sustained fibroblast production of inflammatory mediators. Immunity 46:220–232PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Yan M, Komatsu N, Muro R, Huynh NC, Tomofuji Y et al (2022) ETS1 governs pathological tissue-remodeling programs in disease-associated fibroblasts. Nat Immunol 23:1330–1341PubMedCrossRef Yan M, Komatsu N, Muro R, Huynh NC, Tomofuji Y et al (2022) ETS1 governs pathological tissue-remodeling programs in disease-associated fibroblasts. Nat Immunol 23:1330–1341PubMedCrossRef
39.
Zurück zum Zitat Harre U, Lang SC, Pfeifle R, Rombouts Y, Fruhbeisser S et al (2015) Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat Commun 6:6651PubMedCrossRef Harre U, Lang SC, Pfeifle R, Rombouts Y, Fruhbeisser S et al (2015) Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat Commun 6:6651PubMedCrossRef
40.
Zurück zum Zitat Negishi-Koga T, Gober HJ, Sumiya E, Komatsu N, Okamoto K, Sawa S, Suematsu A, Suda T, Sato K, Takai T, Takayanagi H (2015) Immune complexes regulate bone metabolism through FcRγ signalling. Nat Commun 6:6637PubMedCrossRef Negishi-Koga T, Gober HJ, Sumiya E, Komatsu N, Okamoto K, Sawa S, Suematsu A, Suda T, Sato K, Takai T, Takayanagi H (2015) Immune complexes regulate bone metabolism through FcRγ signalling. Nat Commun 6:6637PubMedCrossRef
41.
Zurück zum Zitat Pfeifle R, Rothe T, Ipseiz N, Scherer HU, Culemann S et al (2017) Regulation of autoantibody activity by the IL-23-T(H)17 axis determines the onset of autoimmune disease. Nat Immunol 18:104–113PubMedCrossRef Pfeifle R, Rothe T, Ipseiz N, Scherer HU, Culemann S et al (2017) Regulation of autoantibody activity by the IL-23-T(H)17 axis determines the onset of autoimmune disease. Nat Immunol 18:104–113PubMedCrossRef
42.
Zurück zum Zitat Komatsu N, Win S, Yan M, Huynh NC, Sawa S, Tsukasaki M, Terashima A, Pluemsakunthai W, Kollias G, Nakashima T, Takayanagi H (2021) Plasma cells promote osteoclastogenesis and periarticular bone loss in autoimmune arthritis. J Clin Invest 131:e143060CrossRefPubMedPubMedCentral Komatsu N, Win S, Yan M, Huynh NC, Sawa S, Tsukasaki M, Terashima A, Pluemsakunthai W, Kollias G, Nakashima T, Takayanagi H (2021) Plasma cells promote osteoclastogenesis and periarticular bone loss in autoimmune arthritis. J Clin Invest 131:e143060CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Hasegawa T, Kikuta J, Sudo T, Matsuura Y, Matsui T, Simmons S, Ebina K, Hirao M, Okuzaki D, Yoshida Y, Hirao A, Kalinichenko VV, Yamaoka K, Takeuchi T, Ishii M (2019) Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1. Nat Immunol 20:1631–1643PubMedCrossRef Hasegawa T, Kikuta J, Sudo T, Matsuura Y, Matsui T, Simmons S, Ebina K, Hirao M, Okuzaki D, Yoshida Y, Hirao A, Kalinichenko VV, Yamaoka K, Takeuchi T, Ishii M (2019) Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1. Nat Immunol 20:1631–1643PubMedCrossRef
44.
Zurück zum Zitat Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156–163PubMedCrossRef Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156–163PubMedCrossRef
45.
Zurück zum Zitat Wehmeyer C, Frank S, Beckmann D, Bottcher M, Cromme C, Konig U, Fennen M, Held A, Paruzel P, Hartmann C, Stratis A, Korb-Pap A, Kamradt T, Kramer I, van den Berg W, Kneissel M, Pap T, Dankbar B (2016) Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction. Sci Transl Med 8:330CrossRef Wehmeyer C, Frank S, Beckmann D, Bottcher M, Cromme C, Konig U, Fennen M, Held A, Paruzel P, Hartmann C, Stratis A, Korb-Pap A, Kamradt T, Kramer I, van den Berg W, Kneissel M, Pap T, Dankbar B (2016) Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction. Sci Transl Med 8:330CrossRef
46.
Zurück zum Zitat Marenzana M, Vugler A, Moore A, Robinson M (2013) Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microCT study. Arthritis Res Ther 15:R125PubMedPubMedCentralCrossRef Marenzana M, Vugler A, Moore A, Robinson M (2013) Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microCT study. Arthritis Res Ther 15:R125PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Ando Y, Tsukasaki M, Huynh NC, Zang S, Yan M, Muro R, Nakamura K, Komagamine M, Komatsu N, Okamoto K, Nakano K, Okamura T, Yamaguchi A, Ishihara K, Takayanagi H (2024) The neutrophil-osteogenic cell axis promotes bone destruction in periodontitis. Int J Oral Sci 16:18PubMedPubMedCentralCrossRef Ando Y, Tsukasaki M, Huynh NC, Zang S, Yan M, Muro R, Nakamura K, Komagamine M, Komatsu N, Okamoto K, Nakano K, Okamura T, Yamaguchi A, Ishihara K, Takayanagi H (2024) The neutrophil-osteogenic cell axis promotes bone destruction in periodontitis. Int J Oral Sci 16:18PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, Gorman DM, Bowman EP, McClanahan TK, Yearley JH, Eberl G, Buckley CD, Kastelein RA, Pierce RH, Laface DM, Cua DJ (2012) IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 18:1069–1076PubMedCrossRef Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, Gorman DM, Bowman EP, McClanahan TK, Yearley JH, Eberl G, Buckley CD, Kastelein RA, Pierce RH, Laface DM, Cua DJ (2012) IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 18:1069–1076PubMedCrossRef
49.
Zurück zum Zitat Venken K, Jacques P, Mortier C, Labadia ME, Decruy T et al (2019) RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients. Nat Commun 10:9PubMedPubMedCentralCrossRef Venken K, Jacques P, Mortier C, Labadia ME, Decruy T et al (2019) RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients. Nat Commun 10:9PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Uluçkan Ö, Jimenez M, Karbach S, Jeschke A, Graña O, Keller J, Busse B, Croxford AL, Finzel S, Koenders M, van den Berg W, Schinke T, Amling M, Waisman A, Schett G, Wagner EF (2016) Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. Sci Transl Med 8:330CrossRef Uluçkan Ö, Jimenez M, Karbach S, Jeschke A, Graña O, Keller J, Busse B, Croxford AL, Finzel S, Koenders M, van den Berg W, Schinke T, Amling M, Waisman A, Schett G, Wagner EF (2016) Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. Sci Transl Med 8:330CrossRef
51.
Zurück zum Zitat Faust HJ, Zhang H, Han J, Wolf MT, Jeon OH, Sadtler K, Pena AN, Chung L, Maestas DR Jr, Tam AJ, Pardoll DM, Campisi J, Housseau F, Zhou D, Bingham CO 3rd, Elisseeff JH (2020) IL-17 and immunologically induced senescence regulate response to injury in osteoarthritis. J Clin Invest 130:5493–5507PubMedPubMedCentralCrossRef Faust HJ, Zhang H, Han J, Wolf MT, Jeon OH, Sadtler K, Pena AN, Chung L, Maestas DR Jr, Tam AJ, Pardoll DM, Campisi J, Housseau F, Zhou D, Bingham CO 3rd, Elisseeff JH (2020) IL-17 and immunologically induced senescence regulate response to injury in osteoarthritis. J Clin Invest 130:5493–5507PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Mori T, Sato Y, Miyamoto K, Kobayashi T, Shimizu T, Kanagawa H, Katsuyama E, Fujie A, Hao W, Tando T, Iwasaki R, Kawana H, Morioka H, Matsumoto M, Saya H, Toyama Y, Miyamoto T (2014) TNFα promotes osteosarcoma progression by maintaining tumor cells in an undifferentiated state. Oncogene 33:4236–4241PubMedCrossRef Mori T, Sato Y, Miyamoto K, Kobayashi T, Shimizu T, Kanagawa H, Katsuyama E, Fujie A, Hao W, Tando T, Iwasaki R, Kawana H, Morioka H, Matsumoto M, Saya H, Toyama Y, Miyamoto T (2014) TNFα promotes osteosarcoma progression by maintaining tumor cells in an undifferentiated state. Oncogene 33:4236–4241PubMedCrossRef
53.
Zurück zum Zitat Yoshimura N, Kariya R, Shimada M, Tateyama M, Matsunaga H et al (2023) The IL-17-IL-17RA axis is required to promote osteosarcoma progression in mice. Sci Rep 13:21572PubMedPubMedCentralCrossRef Yoshimura N, Kariya R, Shimada M, Tateyama M, Matsunaga H et al (2023) The IL-17-IL-17RA axis is required to promote osteosarcoma progression in mice. Sci Rep 13:21572PubMedPubMedCentralCrossRef
54.
Zurück zum Zitat Tsumura M, Miki M, Mizoguchi Y, Hirata O, Nishimura S, Tamaura M, Kagawa R, Hayakawa S, Kobayashi M, Okada S (2022) Enhanced osteoclastogenesis in patients with MSMD due to impaired response to IFN-γ. J Allergy Clin Immunol 149:252–61.e6PubMedCrossRef Tsumura M, Miki M, Mizoguchi Y, Hirata O, Nishimura S, Tamaura M, Kagawa R, Hayakawa S, Kobayashi M, Okada S (2022) Enhanced osteoclastogenesis in patients with MSMD due to impaired response to IFN-γ. J Allergy Clin Immunol 149:252–61.e6PubMedCrossRef
55.
Zurück zum Zitat Ono T, Okamoto K, Nakashima T, Nitta T, Hori S, Iwakura Y, Takayanagi H (2016) IL-17-producing γδ T cells enhance bone regeneration. Nat Commun 7:10928PubMedPubMedCentralCrossRef Ono T, Okamoto K, Nakashima T, Nitta T, Hori S, Iwakura Y, Takayanagi H (2016) IL-17-producing γδ T cells enhance bone regeneration. Nat Commun 7:10928PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Reinke S, Geissler S, Taylor WR, Schmidt-Bleek K, Juelke K, Schwachmeyer V, Dahne M, Hartwig T, Akyüz L, Meisel C, Unterwalder N, Singh NB, Reinke P, Haas NP, Volk HD, Duda GN (2013) Terminally differentiated CD8+ T cells negatively affect bone regeneration in humans. Sci Transl Med 5:177CrossRef Reinke S, Geissler S, Taylor WR, Schmidt-Bleek K, Juelke K, Schwachmeyer V, Dahne M, Hartwig T, Akyüz L, Meisel C, Unterwalder N, Singh NB, Reinke P, Haas NP, Volk HD, Duda GN (2013) Terminally differentiated CD8+ T cells negatively affect bone regeneration in humans. Sci Transl Med 5:177CrossRef
57.
Zurück zum Zitat Vi L, Baht GS, Soderblom EJ, Whetstone H, Wei Q, Furman B, Puviindran V, Nadesan P, Foster M, Poon R, White JP, Yahara Y, Ng A, Barrientos T, Grynpas M, Mosely MA, Alman BA (2018) Macrophage cells secrete factors including LRP1 that orchestrate the rejuvenation of bone repair in mice. Nat Commun 9:5191PubMedPubMedCentralCrossRef Vi L, Baht GS, Soderblom EJ, Whetstone H, Wei Q, Furman B, Puviindran V, Nadesan P, Foster M, Poon R, White JP, Yahara Y, Ng A, Barrientos T, Grynpas M, Mosely MA, Alman BA (2018) Macrophage cells secrete factors including LRP1 that orchestrate the rejuvenation of bone repair in mice. Nat Commun 9:5191PubMedPubMedCentralCrossRef
59.
60.
Zurück zum Zitat Omatsu Y, Sugiyama T, Kohara H, Kondoh G, Fujii N, Kohno K, Nagasawa T (2010) The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity 33:387–399PubMedCrossRef Omatsu Y, Sugiyama T, Kohara H, Kondoh G, Fujii N, Kohno K, Nagasawa T (2010) The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity 33:387–399PubMedCrossRef
61.
Zurück zum Zitat Terashima A, Okamoto K, Nakashima T, Akira S, Ikuta K, Takayanagi H (2016) Sepsis-induced osteoblast ablation causes immunodeficiency. Immunity 44:1434–1443PubMedCrossRef Terashima A, Okamoto K, Nakashima T, Akira S, Ikuta K, Takayanagi H (2016) Sepsis-induced osteoblast ablation causes immunodeficiency. Immunity 44:1434–1443PubMedCrossRef
62.
Zurück zum Zitat Yu VW, Saez B, Cook C, Lotinun S, Pardo-Saganta A, Wang YH, Lymperi S, Ferraro F, Raaijmakers MH, Wu JY, Zhou L, Rajagopal J, Kronenberg HM, Baron R, Scadden DT (2015) Specific bone cells produce DLL4 to generate thymus-seeding progenitors from bone marrow. J Exp Med 212:759–774PubMedPubMedCentralCrossRef Yu VW, Saez B, Cook C, Lotinun S, Pardo-Saganta A, Wang YH, Lymperi S, Ferraro F, Raaijmakers MH, Wu JY, Zhou L, Rajagopal J, Kronenberg HM, Baron R, Scadden DT (2015) Specific bone cells produce DLL4 to generate thymus-seeding progenitors from bone marrow. J Exp Med 212:759–774PubMedPubMedCentralCrossRef
63.
Zurück zum Zitat Ishikawa M, Hasanali ZS, Zhao Y, Das A, Lavaert M, Roman CJ, Londregan J, Allman D, Bhandoola A (2024) Bone marrow plasma cells require P2RX4 to sense extracellular ATP. Nature 626:1102–1107PubMedPubMedCentralCrossRef Ishikawa M, Hasanali ZS, Zhao Y, Das A, Lavaert M, Roman CJ, Londregan J, Allman D, Bhandoola A (2024) Bone marrow plasma cells require P2RX4 to sense extracellular ATP. Nature 626:1102–1107PubMedPubMedCentralCrossRef
64.
Zurück zum Zitat Kode A, Manavalan JS, Mosialou I, Bhagat G, Rathinam CV, Luo N, Khiabanian H, Lee A, Murty VV, Friedman R, Brum A, Park D, Galili N, Mukherjee S, Teruya-Feldstein J, Raza A, Rabadan R, Berman E, Kousteni S (2014) Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature 506:240–244PubMedPubMedCentralCrossRef Kode A, Manavalan JS, Mosialou I, Bhagat G, Rathinam CV, Luo N, Khiabanian H, Lee A, Murty VV, Friedman R, Brum A, Park D, Galili N, Mukherjee S, Teruya-Feldstein J, Raza A, Rabadan R, Berman E, Kousteni S (2014) Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature 506:240–244PubMedPubMedCentralCrossRef
65.
Zurück zum Zitat Dong L, Yu WM, Zheng H, Loh ML, Bunting ST, Pauly M, Huang G, Zhou M, Broxmeyer HE, Scadden DT, Qu CK (2016) Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment. Nature 539:304–308PubMedPubMedCentralCrossRef Dong L, Yu WM, Zheng H, Loh ML, Bunting ST, Pauly M, Huang G, Zhou M, Broxmeyer HE, Scadden DT, Qu CK (2016) Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment. Nature 539:304–308PubMedPubMedCentralCrossRef
66.
Zurück zum Zitat Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA, Ebert BL, Al-Shahrour F, Hasserjian RP, Scadden EO, Aung Z, Matza M, Merkenschlager M, Lin C, Rommens JM, Scadden DT (2010) Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464:852–857PubMedPubMedCentralCrossRef Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA, Ebert BL, Al-Shahrour F, Hasserjian RP, Scadden EO, Aung Z, Matza M, Merkenschlager M, Lin C, Rommens JM, Scadden DT (2010) Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464:852–857PubMedPubMedCentralCrossRef
67.
Zurück zum Zitat Zambetti NA, Ping Z, Chen S, Kenswil KJG, Mylona MA et al (2016) Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia. Cell Stem Cell 19:613–627PubMedCrossRef Zambetti NA, Ping Z, Chen S, Kenswil KJG, Mylona MA et al (2016) Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia. Cell Stem Cell 19:613–627PubMedCrossRef
68.
Zurück zum Zitat Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, Tesio M, Samstein RM, Goichberg P, Spiegel A, Elson A, Lapidot T (2006) Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 12:657–664PubMedCrossRef Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, Tesio M, Samstein RM, Goichberg P, Spiegel A, Elson A, Lapidot T (2006) Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 12:657–664PubMedCrossRef
69.
Zurück zum Zitat Miyamoto K, Yoshida S, Kawasumi M, Hashimoto K, Kimura T et al (2011) Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. J Exp Med 208:2175–2181PubMedPubMedCentralCrossRef Miyamoto K, Yoshida S, Kawasumi M, Hashimoto K, Kimura T et al (2011) Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. J Exp Med 208:2175–2181PubMedPubMedCentralCrossRef
70.
Zurück zum Zitat Takamatsu Y, Simmons PJ, Moore RJ, Morris HA, To LB, Levesque JP (1998) Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Blood 92:3465–3473PubMedCrossRef Takamatsu Y, Simmons PJ, Moore RJ, Morris HA, To LB, Levesque JP (1998) Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Blood 92:3465–3473PubMedCrossRef
71.
Zurück zum Zitat Rao M, Supakorndej T, Schmidt AP, Link DC (2015) Osteoclasts are dispensable for hematopoietic progenitor mobilization by granulocyte colony-stimulating factor in mice. Exp Hematol 43:e1-2CrossRef Rao M, Supakorndej T, Schmidt AP, Link DC (2015) Osteoclasts are dispensable for hematopoietic progenitor mobilization by granulocyte colony-stimulating factor in mice. Exp Hematol 43:e1-2CrossRef
72.
Zurück zum Zitat Mansour A, Anginot A, Mancini SJ, Schiff C, Carle GF, Wakkach A, Blin-Wakkach C (2011) Osteoclast activity modulates B-cell development in the bone marrow. Cell Res 21:1102–1115PubMedPubMedCentralCrossRef Mansour A, Anginot A, Mancini SJ, Schiff C, Carle GF, Wakkach A, Blin-Wakkach C (2011) Osteoclast activity modulates B-cell development in the bone marrow. Cell Res 21:1102–1115PubMedPubMedCentralCrossRef
73.
Zurück zum Zitat Mansour A, Abou-Ezzi G, Sitnicka E, Jacobsen SE, Wakkach A, Blin-Wakkach C (2012) Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow. J Exp Med 209:537–549PubMedPubMedCentralCrossRef Mansour A, Abou-Ezzi G, Sitnicka E, Jacobsen SE, Wakkach A, Blin-Wakkach C (2012) Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow. J Exp Med 209:537–549PubMedPubMedCentralCrossRef
74.
Zurück zum Zitat Adams GB, Chabner KT, Alley IR, Olson DP, Szczepiorkowski ZM, Poznansky MC, Kos CH, Pollak MR, Brown EM, Scadden DT (2006) Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature 439:599–603PubMedCrossRef Adams GB, Chabner KT, Alley IR, Olson DP, Szczepiorkowski ZM, Poznansky MC, Kos CH, Pollak MR, Brown EM, Scadden DT (2006) Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature 439:599–603PubMedCrossRef
75.
Zurück zum Zitat Breuil V, Ticchioni M, Testa J, Roux CH, Ferrari P, Breittmayer JP, Albert-Sabonnadiere C, Durant J, De Perreti F, Bernard A, Euller-Ziegler L, Carle GF (2010) Immune changes in post-menopausal osteoporosis: the Immunos study. Osteoporos Int 21:805–814PubMedCrossRef Breuil V, Ticchioni M, Testa J, Roux CH, Ferrari P, Breittmayer JP, Albert-Sabonnadiere C, Durant J, De Perreti F, Bernard A, Euller-Ziegler L, Carle GF (2010) Immune changes in post-menopausal osteoporosis: the Immunos study. Osteoporos Int 21:805–814PubMedCrossRef
76.
Zurück zum Zitat Zhou X, Chen Y, Zhang Z, Miao J, Chen G, Qian Z (2024) Identification of differentially expressed genes, signaling pathways and immune infiltration in postmenopausal osteoporosis by integrated bioinformatics analysis. Heliyon 10:e23794PubMedCrossRef Zhou X, Chen Y, Zhang Z, Miao J, Chen G, Qian Z (2024) Identification of differentially expressed genes, signaling pathways and immune infiltration in postmenopausal osteoporosis by integrated bioinformatics analysis. Heliyon 10:e23794PubMedCrossRef
77.
Zurück zum Zitat D’Amelio P (2013) The immune system and postmenopausal osteoporosis. Immunol Invest 42:544–554PubMedCrossRef D’Amelio P (2013) The immune system and postmenopausal osteoporosis. Immunol Invest 42:544–554PubMedCrossRef
78.
Zurück zum Zitat Yu M, Pal S, Paterson CW, Li JY, Tyagi AM, Adams J, Coopersmith CM, Weitzmann MN, Pacifici R (2021) Ovariectomy induces bone loss via microbial-dependent trafficking of intestinal TNF+ T cells and Th17 cells. J Clin Invest 131:e143137PubMedPubMedCentralCrossRef Yu M, Pal S, Paterson CW, Li JY, Tyagi AM, Adams J, Coopersmith CM, Weitzmann MN, Pacifici R (2021) Ovariectomy induces bone loss via microbial-dependent trafficking of intestinal TNF+ T cells and Th17 cells. J Clin Invest 131:e143137PubMedPubMedCentralCrossRef
79.
Zurück zum Zitat Ambrosi TH, Marecic O, McArdle A, Sinha R, Gulati GS et al (2021) Aged skeletal stem cells generate an inflammatory degenerative niche. Nature 597:256–262PubMedPubMedCentralCrossRef Ambrosi TH, Marecic O, McArdle A, Sinha R, Gulati GS et al (2021) Aged skeletal stem cells generate an inflammatory degenerative niche. Nature 597:256–262PubMedPubMedCentralCrossRef
80.
Zurück zum Zitat Ferguson VL, Ayers RA, Bateman TA, Simske SJ (2003) Bone development and age-related bone loss in male C57BL/6J mice. Bone 33:387–398PubMedCrossRef Ferguson VL, Ayers RA, Bateman TA, Simske SJ (2003) Bone development and age-related bone loss in male C57BL/6J mice. Bone 33:387–398PubMedCrossRef
81.
Zurück zum Zitat Pang WW, Price EA, Sahoo D, Beerman I, Maloney WJ, Rossi DJ, Schrier SL, Weissman IL (2011) Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci U S A 108:20012–20017PubMedPubMedCentralCrossRef Pang WW, Price EA, Sahoo D, Beerman I, Maloney WJ, Rossi DJ, Schrier SL, Weissman IL (2011) Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci U S A 108:20012–20017PubMedPubMedCentralCrossRef
82.
Zurück zum Zitat Mitchell CA, Verovskaya EV, Calero-Nieto FJ, Olson OC, Swann JW, Wang X, Herault A, Dellorusso PV, Zhang SY, Svendsen AF, Pietras EM, Bakker ST, Ho TT, Gottgens B, Passegue E (2023) Stromal niche inflammation mediated by IL-1 signalling is a targetable driver of haematopoietic ageing. Nat Cell Biol 25:30–41PubMedPubMedCentralCrossRef Mitchell CA, Verovskaya EV, Calero-Nieto FJ, Olson OC, Swann JW, Wang X, Herault A, Dellorusso PV, Zhang SY, Svendsen AF, Pietras EM, Bakker ST, Ho TT, Gottgens B, Passegue E (2023) Stromal niche inflammation mediated by IL-1 signalling is a targetable driver of haematopoietic ageing. Nat Cell Biol 25:30–41PubMedPubMedCentralCrossRef
83.
Zurück zum Zitat Li CJ, Xiao Y, Sun YC, He WZ, Liu L, Huang M, He C, Huang M, Chen KX, Hou J, Feng X, Su T, Guo Q, Huang Y, Peng H, Yang M, Liu GH, Luo XH (2021) Senescent immune cells release grancalcin to promote skeletal aging. Cell Metab 33:1957–1973PubMedCrossRef Li CJ, Xiao Y, Sun YC, He WZ, Liu L, Huang M, He C, Huang M, Chen KX, Hou J, Feng X, Su T, Guo Q, Huang Y, Peng H, Yang M, Liu GH, Luo XH (2021) Senescent immune cells release grancalcin to promote skeletal aging. Cell Metab 33:1957–1973PubMedCrossRef
84.
Zurück zum Zitat Biswas L, Chen J, De Angelis J, Singh A, Owen-Woods C, Ding Z, Pujol JM, Kumar N, Zeng F, Ramasamy SK, Kusumbe AP (2023) Lymphatic vessels in bone support regeneration after injury. Cell 186:382–397PubMedCrossRef Biswas L, Chen J, De Angelis J, Singh A, Owen-Woods C, Ding Z, Pujol JM, Kumar N, Zeng F, Ramasamy SK, Kusumbe AP (2023) Lymphatic vessels in bone support regeneration after injury. Cell 186:382–397PubMedCrossRef
85.
Zurück zum Zitat Frodermann V, Rohde D, Courties G, Severe N, Schloss MJ et al (2019) Exercise reduces inflammatory cell production and cardiovascular inflammation via instruction of hematopoietic progenitor cells. Nat Med 25:1761–1771PubMedPubMedCentralCrossRef Frodermann V, Rohde D, Courties G, Severe N, Schloss MJ et al (2019) Exercise reduces inflammatory cell production and cardiovascular inflammation via instruction of hematopoietic progenitor cells. Nat Med 25:1761–1771PubMedPubMedCentralCrossRef
86.
Zurück zum Zitat Peng H, Hu B, Xie LQ, Su T, Li CJ, Liu Y, Yang M, Xiao Y, Feng X, Zhou R, Guo Q, Zhou HY, Huang Y, Jiang TJ, Luo XH (2022) A mechanosensitive lipolytic factor in the bone marrow promotes osteogenesis and lymphopoiesis. Cell Metab 34:1168–1182PubMedCrossRef Peng H, Hu B, Xie LQ, Su T, Li CJ, Liu Y, Yang M, Xiao Y, Feng X, Zhou R, Guo Q, Zhou HY, Huang Y, Jiang TJ, Luo XH (2022) A mechanosensitive lipolytic factor in the bone marrow promotes osteogenesis and lymphopoiesis. Cell Metab 34:1168–1182PubMedCrossRef
87.
Zurück zum Zitat Nagai M, Noguchi R, Takahashi D, Morikawa T, Koshida K et al (2019) Fasting-refeeding impacts immune cell dynamics and mucosal immune responses. Cell 178:1072–1087PubMedCrossRef Nagai M, Noguchi R, Takahashi D, Morikawa T, Koshida K et al (2019) Fasting-refeeding impacts immune cell dynamics and mucosal immune responses. Cell 178:1072–1087PubMedCrossRef
88.
Zurück zum Zitat Collins N, Han SJ, Enamorado M, Link VM, Huang B, Moseman EA, Kishton RJ, Shannon JP, Dixit D, Schwab SR, Hickman HD, Restifo NP, McGavern DB, Schwartzberg PL, Belkaid Y (2019) The bone marrow protects and optimizes immunological memory during dietary restriction. Cell 178:1088–1101PubMedPubMedCentralCrossRef Collins N, Han SJ, Enamorado M, Link VM, Huang B, Moseman EA, Kishton RJ, Shannon JP, Dixit D, Schwab SR, Hickman HD, Restifo NP, McGavern DB, Schwartzberg PL, Belkaid Y (2019) The bone marrow protects and optimizes immunological memory during dietary restriction. Cell 178:1088–1101PubMedPubMedCentralCrossRef
89.
Zurück zum Zitat Engblom C, Pfirschke C, Zilionis R, Da Silva MJ, Bos SA et al (2017) Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils. Science 358:eaal5081CrossRefPubMedPubMedCentral Engblom C, Pfirschke C, Zilionis R, Da Silva MJ, Bos SA et al (2017) Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils. Science 358:eaal5081CrossRefPubMedPubMedCentral
90.
Zurück zum Zitat D’Amico L, Mahajan S, Capietto AH, Yang Z, Zamani A, Ricci B, Bumpass DB, Meyer M, Su X, Wang-Gillam A, Weilbaecher K, Stewart SA, DeNardo DG, Faccio R (2016) Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer. J Exp Med 213:827–840PubMedPubMedCentralCrossRef D’Amico L, Mahajan S, Capietto AH, Yang Z, Zamani A, Ricci B, Bumpass DB, Meyer M, Su X, Wang-Gillam A, Weilbaecher K, Stewart SA, DeNardo DG, Faccio R (2016) Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer. J Exp Med 213:827–840PubMedPubMedCentralCrossRef
Metadaten
Titel
Crosstalk between bone and the immune system
verfasst von
Kazuo Okamoto
Publikationsdatum
26.07.2024
Verlag
Springer Nature Singapore
Erschienen in
Journal of Bone and Mineral Metabolism / Ausgabe 4/2024
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-024-01539-x

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Vorhofflimmern: Antikoagulation vor Schlaganfall von Vorteil

Erleiden Menschen mit Vorhofflimmern einen ischämischen Schlaganfall, ist dieser weniger schwer, auch sind Infarktgröße und Blutungsrisiko geringer, wenn sie zuvor orale Antikoagulanzien erhalten haben. Die Art der Antikoagulation spielt dabei keine Rolle.

Frühe CLL-Therapie: BTK-Hemmer verlängert EFS und PFS, aber nicht OS

Auch nach sechs Jahren ergibt sich kein Überlebensvorteil einer Therapie mit dem BTK-Hemmer Ibrutinib für Menschen mit frühem CLL-Stadium und erhöhtem Progressionsrisiko. Die Progressionsrate wird mit der Behandlung jedoch um über 80% gesenkt.

Mehr Cholesterin im Essen = höheres Herzinfarktrisiko

Je mehr Cholesterin man täglich über die Nahrung zu sich nimmt, desto höher ist offenbar das Herzinfarktrisiko – das legt eine Studie mit US-Veteranen zumindest für Männer nahe.

Antikoagulation bei Vorhofflimmern: Sind DOAK noch zu toppen?

Gegen Thromboembolien so wirksam wie ein DOAK, bei zugleich geringerem Blutungsrisiko – werden Faktor-XI-Hemmer als neue Antikoagulanzien dieser Erwartung gerecht? Eine aktuell publizierte Vergleichsstudie gibt darüber Aufschluss.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.